Industry: Pharmaceuticals, Biotechnology
Amarillo Biosciences, Inc., is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 13.5% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company’s primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Behçet’s disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for oral interferon therapies. ( www.amarbio.com )
Amarillo Biosciences Inc
4134 Business Park Drive
Amarillo, Texas 79110-4225
USA
Tel: (806) 376-1741
Fax: (806) 376-9301